Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping. [electronic resource]
Producer: 20180223Description: 669-675 p. digitalISSN:- 1534-4681
- Adult
- Aged
- Aged, 80 and over
- Anastrozole
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Aromatase Inhibitors -- therapeutic use
- Breast Neoplasms -- classification
- Bridged-Ring Compounds -- administration & dosage
- Chemotherapy, Adjuvant
- Clinical Decision-Making
- Cyclophosphamide -- administration & dosage
- Docetaxel
- Doxorubicin -- administration & dosage
- Female
- Gene Expression Profiling
- Humans
- Immunohistochemistry
- In Situ Hybridization, Fluorescence
- Letrozole
- Mastectomy, Segmental
- Middle Aged
- Molecular Typing -- methods
- Neoadjuvant Therapy
- Nitriles -- administration & dosage
- Prospective Studies
- Receptor, ErbB-2 -- metabolism
- Receptors, Estrogen -- metabolism
- Receptors, Progesterone -- metabolism
- Registries
- Tamoxifen -- administration & dosage
- Taxoids -- administration & dosage
- Treatment Outcome
- Triazoles -- administration & dosage
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase IV; Comparative Study; Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.